These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses. Govorkova EA; Leneva IA; Goloubeva OG; Bush K; Webster RG Antimicrob Agents Chemother; 2001 Oct; 45(10):2723-32. PubMed ID: 11557461 [TBL] [Abstract][Full Text] [Related]
8. Efficacy of zanamivir against avian influenza A viruses that possess genes encoding H5N1 internal proteins and are pathogenic in mammals. Leneva IA; Goloubeva O; Fenton RJ; Tisdale M; Webster RG Antimicrob Agents Chemother; 2001 Apr; 45(4):1216-24. PubMed ID: 11257037 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of influenza virus replication in mice by GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is consistent with extracellular activity of viral neuraminidase (sialidase). Ryan DM; Ticehurst J; Dempsey MH; Penn CR Antimicrob Agents Chemother; 1994 Oct; 38(10):2270-5. PubMed ID: 7840556 [TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. Hayden FG; Treanor JJ; Betts RF; Lobo M; Esinhart JD; Hussey EK JAMA; 1996 Jan 24-31; 275(4):295-9. PubMed ID: 8544269 [TBL] [Abstract][Full Text] [Related]
11. Immunological effects of the orally administered neuraminidase inhibitor oseltamivir in influenza virus-infected and uninfected mice. Burger RA; Billingsley JL; Huffman JH; Bailey KW; Kim CU; Sidwell RW Immunopharmacology; 2000 Apr; 47(1):45-52. PubMed ID: 10708809 [TBL] [Abstract][Full Text] [Related]
12. Influence of virus strain, challenge dose, and time of therapy initiation on the in vivo influenza inhibitory effects of RWJ-270201. Sidwell RW; Smee DF; Huffman JH; Barnard DL; Morrey JD; Bailey KW; Feng WC; Babu YS; Bush K Antiviral Res; 2001 Sep; 51(3):179-87. PubMed ID: 11448729 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. Hayden FG; Osterhaus AD; Treanor JJ; Fleming DM; Aoki FY; Nicholson KG; Bohnen AM; Hirst HM; Keene O; Wightman K N Engl J Med; 1997 Sep; 337(13):874-80. PubMed ID: 9302301 [TBL] [Abstract][Full Text] [Related]
15. Surveillance for neuraminidase inhibitor resistance in human influenza viruses from Australia. Hurt AC; Barr IG; Durrant CJ; Shaw RP; Sjogren HM; Hampson AW Commun Dis Intell Q Rep; 2003; 27(4):542-7. PubMed ID: 15508516 [TBL] [Abstract][Full Text] [Related]
16. Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en. Gubareva LV; Robinson MJ; Bethell RC; Webster RG J Virol; 1997 May; 71(5):3385-90. PubMed ID: 9094607 [TBL] [Abstract][Full Text] [Related]
17. Penetration of GS4071, a novel influenza neuraminidase inhibitor, into rat bronchoalveolar lining fluid following oral administration of the prodrug GS4104. Eisenberg EJ; Bidgood A; Cundy KC Antimicrob Agents Chemother; 1997 Sep; 41(9):1949-52. PubMed ID: 9303391 [TBL] [Abstract][Full Text] [Related]
18. Anti-influenza virus activity of the neuraminidase inhibitor 4-guanidino-Neu5Ac2en in cell culture and in human respiratory epithelium. Hayden FG; Rollins BS; Madren LK Antiviral Res; 1994 Oct; 25(2):123-31. PubMed ID: 7847874 [TBL] [Abstract][Full Text] [Related]